Search

Your search keyword '"Lorraine A. Chantrill"' showing total 2 results
Start Over Author "Lorraine A. Chantrill" Publication Year Range Last 3 years
2 results on '"Lorraine A. Chantrill"'

1. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence

Author

Stephan B. Dreyer, Rosie Upstill-Goddard, Assya Legrini, Andrew V. Biankin, Nigel B. Jamieson, David K. Chang, Sarah Allison, Dario Beraldi, Euan Cameron, Susanna L. Cooke, Richard Cunningham, Stephan Dreyer, Paul Grimwood, Shane Kelly, John Marshall, Brian McDade, Elizabeth A. Musgrove, Donna Ramsay, Lisa Evers, Selma Rebus, Lola Rahib, Bryan Serrels, Colin J. McKay, Paul Westwood, Nicola Williams, Fraser Duthie, William Shen, Antonio Pea, Amber L. Johns, Anthony J. Gill, Lorraine A. Chantrill, Paul Timpson, Angela Chou, Marina Pajic, Tanya Dwarte, David Herrmann, Claire Vennin, Thomas R. Cox, Brooke Pereira, Shona Ritchiee, Daniel A. Reed, Cecilia R. Chambers, Xanthe Metcalf, Max Nobis, Gloria Jeong, Lara Kenyon, Ruth J. Lyons, Nicola Waddell, John V. Pearson, Ann-Marie Patch, Katia Nones, Felicity Newell, Pamela Mukhopadhyay, Venkateswar Addala, Stephen Kazakoff, Oliver Holmes, Conrad Leonard, Scott Wood, Sean M. Grimmond, Oliver Hofmann, Jaswinder S. Samra, Nick Pavlakis, Jennifer Arena, Hilda A. High, Ray Asghari, Neil D. Merrett, Amitabha Das, Peter H. Cosman, Kasim Ismail, Alina Stoita, David Williams, Allan Spigellman, Duncan McLeod, Judy Kirk, James G. Kench, Peter Grimison, Charbel Sandroussi, Annabel Goodwin, R. Scott Mead, Katherine Tucker, Lesley Andrews, Michael Texler, Cindy Forrest, Mo Ballal, David Fletcher, Maria Beilin, Kynan Feeney, Krishna Epari, Sanjay Mukhedkar, Nikolajs Zeps, Nan Q. Nguyen, Andrew R. Ruszkiewicz, Chris Worthley, John Chen, Mark E. Brooke-Smith, Virginia Papangelis, Andrew D. Clouston, Andrew P. Barbour, Thomas J. O’Rourke, Jonathan W. Fawcett, Kellee Slater, Michael Hatzifotis, Peter Hodgkinson, Mehrdad Nikfarjam, James R. Eshleman, Ralph H. Hruban, Christopher L. Wolfgang, Aldo Scarpa, Rita T. Lawlor, Vincenzo Corbo, and Claudio Bassi

Subjects
Oncology, medicine.medical_specialty, Lung Neoplasms, Time Factors, MEDLINE, Biology, Risk Assessment, Disease-Free Survival, Pancreatectomy, Risk Factors, Internal medicine, Pancreatic cancer, Research Letter, medicine, Biomarkers, Tumor, Humans, Tumor, Hepatology, Liver Neoplasms, Gastroenterology, Genomics, medicine.disease, Pancreatic Neoplasms, Neoplasm Recurrence, Local, Neoplasm Recurrence, Local, Biomarkers
Published
2022

2. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty

Author

Daniel J. Renouf, Timothy J. Price, M. Burge, Lorraine A. Chantrill, Jeremy Shapiro, John W. Chen, Ian Chau, Amitesh Roy, Trevor Leong, Niall C. Tebbutt, Florian Lordick, Nick Pavlakis, David Goldstein, Eva Segelov, Christos S. Karapetis, Adnan Nagrial, and Mike Nguyen

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, MEDLINE, Disease, Malignancy, medicine.disease, Faculty, Optimal management, Neoadjuvant Therapy, Clinical trial, Pancreatic Neoplasms, Oncology, Chemotherapy, Adjuvant, Pancreatic cancer, medicine, Humans, Pharmacology (medical), Personalized medicine, Intensive care medicine, business, Neoadjuvant therapy
Abstract

Introduction Pancreatic cancer remains a challenging malignancy due to the high proportion of patients diagnosed at advanced stages and the limited treatment options. This article discusses recent evidence in the management of both localised and advanced pancreatic cancer and offers an expert opinion on current best practice. Areas covered For patients with localised disease, the evidence for adjuvant chemotherapy is discussed as well as emerging neoadjuvant approaches for resectable, borderline resectable and locally advanced disease. Advances in metastatic disease are discussed including cytotoxic chemotherapy, targeted therapies and the role of genomic testing to identify patients with molecular alterations. Reviewed literature included; journal publications, abstracts presented at major international oncology meetings and ongoing clinical trials databases. Expert opinion Pancreatic cancer is a devastating diagnosis and despite recent advances has a very poor prognosis. Only a minority of patients, 20%, are diagnosed with potentially curable disease. The shifting paradigm towards neoadjuvant therapy may improve resectability and survival rates however robust evidence is required. Thus far, there has only been limited progress in advanced stage disease. Genomic testing may potentially identify more treatment targets although limited to small subgroups.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results